AQUIPTA Abbvie Pty Ltd
Product name
AQUIPTA
Sponsor
Accepted date
Jul-2026
Active ingredients
atogepant
Summary of proposed indication
AQUIPTA (atogepant) is proposed for the acute treatment of migraine, with or without aura, in adults. A migraine aura may temporarily cause visual disturbances, sensory changes or affect speech. It can be a warning sign that a migraine is starting and may continue during a migraine.
Application type
C (new indication)
Publication date
Jul-2026